
APLAR 2022 Hong Kong partner prospectus now available
APLAR has a range of opportunities available for interested supporters of the 24th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2022).
For more information please contact our APLAR Industry Liaison:
APLAR Industry Liaison
Thomas Howden
+61 2 9213 4016
thomas.howden@mci-group.com
Important dates
19 November 2021
APLAR ranked partner application deadline
3 December 2021
Unranked partner applications open
THANK YOU FOR YOUR SUPPORT
Industry Partners
APLAR has a range of opportunities available for interested supporters of the 24th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2022).
Diamond Partners

GSK are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer.
Every day, they help improve the health of millions of people around the world by discovering, developing and manufacturing innovative medicines, vaccines and consumer healthcare products.
GSK are building a stronger purpose and performance culture underpinned by our values and expectations - so that together we can deliver extraordinary impact for patients and consumers and make GSK a brilliant place to work.
Their values are Patient focus, Transparency, Respect, Integrity.
Our expectations are Courage, Accountability, Development, Teamwork.
Platinum Partners

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Gold Partners
As a new biopharmaceutical company, AbbVie combines the expertise of a recognised pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, while our services and partnerships help us create greater access and outcomes for the health of all Australians.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.
Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
At Janssen, they're creating a future where disease is a thing of the past. Janssen is the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. They focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

A global biopharma company, focusing on neurology and immunology.
Their vision
UCB’s ambition is to transform the lives of people living with severe diseases. They focus on neurology and immunology disorders – putting patients at the center of our world. They are Inspired by Patients. Driven by Science.
UCB is continuously working to advance science and embrace new knowledge. They are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire them to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives

As a new biopharmaceutical company, AbbVie combines the expertise of a recognised pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, while our services and partnerships help us create greater access and outcomes for the health of all Australians.

At Janssen, they're creating a future where disease is a thing of the past. Janssen is the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. They focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

A global biopharma company, focusing on neurology and immunology.
Their vision
UCB’s ambition is to transform the lives of people living with severe diseases. They focus on neurology and immunology disorders – putting patients at the center of our world. They are Inspired by Patients. Driven by Science.
UCB is continuously working to advance science and embrace new knowledge. They are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire them to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives
Industry Program Sponsors
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of
19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: www.annualreport.boehringer-ingelheim.com.
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
Gilead’s inflammation team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions through a comprehensive clinical trial program evaluating novel agents with the goal of advancing patient care.
As a new biopharmaceutical company, AbbVie combines the expertise of a recognised pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, while our services and partnerships help us create greater access and outcomes for the health of all Australians.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. We consistently rank among the world’s top companies investing in research and development.
As a new biopharmaceutical company, AbbVie combines the expertise of a recognised pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, while our services and partnerships help us create greater access and outcomes for the health of all Australians.
Exhibitors
Supporting Organisations
